618 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 2,428 published Semaglutide COA source records from third-party laboratories, covering 609 publicly attributable vendor identities. Across 2,222 records with positive numeric purity, the arithmetic mean is 99.66%. 12 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 3 positive purity results are below 90%; 90 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $5.50 | $5.50–$5.50 | $1.10 | 1 source · 1 offer |
| 10 mg | $8.00 | $8.00–$8.00 | $0.80 | 1 source · 1 offer |
| 15 mg | $9.50 | $9.00–$10.00 | $0.63 | 2 sources · 2 offers |
| 20 mg | $11.83 | $10.50–$13.00 | $0.59 | 3 sources · 3 offers |
| 30 mg | $16.00 | $14.00–$18.00 | $0.53 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T23:46:29.047508+00:00. Calculation time is not a laboratory observation date.
Within that total, 482 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 45 | 99.8% | 0 of 40 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #2 | 34 | 99.48% | 0 of 30 (0.0%) 0 0% / not detected · 0 wrong compound · 4 unclassified | Reveal with Pro → | |
| #3 | 29 | 99.43% | 0 of 29 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120870 (99.76%) · #120569 (99.95%) · #120845 (99.8%) · #120837 (99.85%) · #120830 (99.79%) · #120620 (99.57%)
If **Bofanglutide (GZR18)** demonstrates superior or comparable efficacy with a favorable safety profile, it could offer a valuable new option for individuals managing **overweight** or **obesity**, particularly those…
If successful, this trial could establish **semaglutide** as a novel therapeutic option for **Alcohol Use Disorder (AUD)**, addressing a significant unmet medical need. Current AUD treatments have limited efficacy for…
This case report significantly expands the known safety profile of **semaglutide**, highlighting a rare but serious potential complication: **spontaneous pneumomediastinum**. For peptide users and biohackers, this und…
This research identifies a novel mechanism by which `GLP-1R` activation, specifically with semaglutide, could offer a therapeutic avenue for **alcohol withdrawal-induced anxiety**. Given the high rates of relapse driv…
This real-world evidence strongly reinforces **semaglutide's superior effectiveness over dulaglutide for improving glycemic control and promoting weight loss in a broad Type 2 Diabetes population**. The finding that b…
Semaglutide significantly cut `HbA1c` by **0.71%**, weight by **4.77 kg**, and `SBP` by **3.56 mmHg** in UAE adults with **Type 2 Diabetes** over 12 months.
This review provides a critical roadmap for developing more effective and convenient oral **semaglutide** formulations, potentially expanding access and improving adherence for patients with **type 2 diabetes** and **…
This trial's approach to guiding cardioprotective therapy via a **`proteomic risk model`** could revolutionize how **Type 2 Diabetes (T2D)** patients receive crucial **CVD** prevention. If successful, such a model cou…
While the abstract does not present the findings of this specific study, the *intent* to generate real-world comparative effectiveness data for **semaglutide** and **dulaglutide** is highly significant. **Robust real-…
This case underscores a previously unreported but serious complication of GLP-1 RA therapy: transmural esophageal rupture, likely precipitated by drug-induced gastroparesis and forceful emesis. **Abrupt reinitiation o…
For individuals using **oral semaglutide** for obesity, **strict adherence to the specific administration protocol is paramount for achieving therapeutic efficacy**. This guidance underscores that skipping the `30-min…
This innovative method significantly **reduces the cost and complexity of generating radiolabeled peptides**, a critical bottleneck in peptide drug discovery and development. For researchers and biohackers working wit…
**Implementing a standardized 4-week semaglutide discontinuation protocol before aesthetic abdominoplasty is crucial for patient safety and improved surgical outcomes.** This finding provides clear, actionable guidanc…
Pharmacovigilance data links **GLP-1 receptor agonists**, particularly **semaglutide**, to gastric motility disorders, with semaglutide showing an ROR of **80.27** for impaired gastric emptying.
Multiple systematic reviews and meta-analyses investigate the rate and risk of nonarteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide use for diabetes and weight loss.
Semaglutide's influence on the pharmacokinetics of single doses of atorvastatin and digoxin is being investigated in healthy subjects.
An exploratory study is evaluating the efficacy and safety of **CS0159** combined with **Semaglutide** in patients with **MASH**, obesity, and type 2 diabetes.
A Canadian retrospective study is evaluating real-world semaglutide use on cardio-kidney-metabolic outcomes in adults with **T2D** and obesity.
If successful, this study could significantly impact the management of **Type 2 Diabetes** by establishing a more effective and potentially safer combination therapy. **The practical takeaway for clinicians and patien…
If successful, this Phase 2 trial could validate **TriGlytza®** as a superior long-term treatment for **Type 2 diabetes**, moving beyond symptomatic relief to address root causes like **inflammation** and **insulin re…
**If the ASSET trial demonstrates positive results, Semaglutide could revolutionize acute ischemic stroke management**, offering a critical adjunctive neuroprotective therapy beyond current reperfusion strategies. Thi…
The findings from this pharmacokinetic study are foundational for the safe and effective clinical use of **enlicitide decanoate** and **semaglutide** in combination. As patients with metabolic syndrome often present w…
This trial design is pivotal for advancing **individualized medical weight loss treatment**. By identifying potential predictors of response to obesity medication, clinicians could eventually tailor therapies more eff…
This real-world comparison provides crucial evidence that **patients with Type 2 Diabetes Mellitus can expect similar improvements in glycemic control and weight reduction regardless of whether they choose oral or sub…
This real-world data reinforces the dose-dependent efficacy of semaglutide in achieving significant glycemic control and reducing insulin requirements in **Type 2 Diabetes Mellitus** patients. **Clinicians can confide…
This meta-analysis reinforces the substantial efficacy of **GLP-1RA and incretin-based therapies for weight loss**, particularly when integrated with lifestyle interventions. For individuals managing overweight or obe…
**This consensus provides a critical roadmap for improving early detection and management of steatotic liver disease (SLD)**. For clinicians, it underscores the urgent need to integrate non-invasive fibrosis assessmen…
This research highlights a critical gap in public health policy across Europe, indicating that current frameworks are ill-equipped to manage the growing burden of **MASLD/MASH**. For clinicians and policymakers, the p…
This study highlights a novel therapeutic strategy for **pulmonary arterial hypertension** by targeting **ZIP12** and intracellular zinc. For biohackers and clinicians, **APL-9796** represents a potential new class of…
**Semaglutide** weight loss videos on YouTube often lack reliability. A study of **100** top videos found user-generated content low quality, academic sources higher.
This meta-analysis solidifies semaglutide's role as a potent therapeutic agent for **metabolic dysfunction-associated steatohepatitis (MASH)**, particularly in achieving histological resolution and reducing hepatic fa…
This real-world observational study is critical for understanding how **semaglutide** performs in a diverse clinical setting outside of highly controlled randomized trials, specifically within the Argentine population…
This Phase II trial is crucial for determining if **BGM0504** could offer a new, effective treatment option for **Type 2 Diabetes**, particularly for Chinese patients. If successful, it could provide an alternative or…
A randomized clinical trial will compare the pharmacokinetics of two semaglutide formulations delivered via different pen-injectors in individuals with overweight or obesity.
This comprehensive meta-analysis provides strong reassurance that **oral semaglutide's real-world effectiveness and safety are consistent with its performance in controlled clinical trials**, validating its widespread…
This analysis provides critical pharmacoeconomic evidence for **clinical decision-making and health policy formulation in China**, particularly regarding the inclusion and reimbursement of `GLP-1R` agonists. The findi…
A comprehensive meta-analysis of real-world evidence confirms oral semaglutide's efficacy and safety in managing **type 2 diabetes** and **obesity**.
Optimizing oral peptide delivery is critical for patient adherence and broader therapeutic access. This study's investigation into **semaglutide** Formulation III, particularly its focus on water volume and meal timin…
If successful, this trial could establish **semaglutide** as a novel therapeutic strategy to mitigate severe GI complications associated with auto-HSCT, significantly improving patient quality of life and reducing inf…
This Phase II trial is crucial for advancing treatment options for **MASH** and **obesity**, conditions with significant unmet medical needs. **If successful**, the combination of **CS060380** with semaglutide could o…
This research significantly advances our understanding of how `GLP-1RAs` like **semaglutide** exert their neuroprotective effects, moving beyond general anti-inflammatory observations to specific cellular and transcri…
This large real-world study provides compelling evidence for the broad metabolic benefits of **oral semaglutide** in routine clinical practice, extending beyond glycemic control and weight loss to include significant …
This preclinical study offers a promising strategy for individuals using GLP-1RAs like semaglutide to manage **obesity**, particularly for those concerned about **muscle loss**. **Co-administering ketone esters could …
Elecoglipron, an oral small molecule `GLP-1` receptor agonist, was evaluated for efficacy, safety, and tolerability in a 26-week Phase 2b trial for **type 2 diabetes**.
This study underscores a critical need for enhanced digital health literacy among individuals seeking information on **semaglutide** for weight loss. **Viewers should prioritize content from academic or healthcare-aff…
This research highlights a critical safety concern for patients on GLP-1 receptor agonists like semaglutide who require anesthesia. **Anesthesiologists may need to adapt pre-operative fasting guidelines or implement a…
The ongoing investigation of **NNC0662-0419** represents a crucial step in potentially expanding the therapeutic arsenal for **Type 2 Diabetes**. If proven effective and safe, this novel compound could offer a new opt…
**Understanding drug-drug interactions is paramount for safe and effective patient care.** If semaglutide significantly alters the pharmacokinetics or pharmacodynamics of **warfarin**, dosage adjustments or increased …
**Direct comparison of Lactobacillus paracasei LC-19 and semaglutide** for weight management and metabolic health is significant. The findings could **inform individualized intervention strategies**, offering a potent…
If successful, **ACM-001.1** could significantly improve the quality of weight loss achieved with semaglutide, shifting the focus from mere weight reduction to optimized body composition. This would be a major step to…
Free, no account — handy when you're working with Semaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account